Evolus Inc (NASDAQ:EOLS) Short Interest Update

Evolus Inc (NASDAQ:EOLS) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 4,365,600 shares, a decrease of 5.9% from the June 30th total of 4,637,300 shares. Based on an average daily volume of 807,400 shares, the days-to-cover ratio is currently 5.4 days. Currently, 38.1% of the shares of the company are short sold.

EOLS opened at $14.05 on Friday. The company has a debt-to-equity ratio of 1.87, a current ratio of 5.01 and a quick ratio of 14.52. The business has a 50 day simple moving average of $16.51 and a 200-day simple moving average of $20.48. The stock has a market capitalization of $410.00 million, a P/E ratio of -8.95 and a beta of 4.80. Evolus has a 12 month low of $10.22 and a 12 month high of $30.25.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Monday, August 12th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.41). The firm had revenue of $2.30 million during the quarter, compared to analyst estimates of $0.29 million. Research analysts anticipate that Evolus will post -3.43 EPS for the current year.

In related news, Director Vikram Malik acquired 1,298,701 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was bought at an average cost of $19.25 per share, with a total value of $24,999,994.25. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Simone Blank acquired 628,536 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were bought at an average cost of $19.25 per share, with a total value of $12,099,318.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 1,931,327 shares of company stock valued at $37,157,482. Insiders own 3.90% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of Evolus by 12.2% in the 2nd quarter. BlackRock Inc. now owns 994,396 shares of the company’s stock valued at $14,540,000 after buying an additional 107,946 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Evolus by 46.3% in the 2nd quarter. Vanguard Group Inc. now owns 710,230 shares of the company’s stock valued at $10,384,000 after buying an additional 224,758 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Evolus in the 2nd quarter valued at approximately $4,167,000. Wafra Inc. lifted its holdings in shares of Evolus by 106.2% in the 2nd quarter. Wafra Inc. now owns 203,263 shares of the company’s stock valued at $2,972,000 after buying an additional 104,706 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Evolus by 4.2% in the 2nd quarter. Northern Trust Corp now owns 164,574 shares of the company’s stock valued at $2,406,000 after buying an additional 6,575 shares during the period. 14.53% of the stock is owned by institutional investors and hedge funds.

A number of analysts have weighed in on the company. Barclays assumed coverage on Evolus in a research report on Tuesday, June 11th. They set an “underweight” rating and a $13.00 price objective for the company. Mizuho set a $31.00 price objective on Evolus and gave the stock a “buy” rating in a research report on Monday, May 20th. ValuEngine raised Evolus from a “hold” rating to a “buy” rating in a research report on Thursday, July 18th. Wells Fargo & Co assumed coverage on Evolus in a research report on Friday, June 28th. They set a “market perform” rating and a $16.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 price objective on shares of Evolus in a research report on Tuesday, April 30th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Evolus presently has an average rating of “Buy” and an average price target of $26.78.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Article: Front-End Load

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.